Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD

Title: Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD
Creator: Gibson, Peter G.
Relation: The European Respiratory Journal Vol. 42, Issue 4, p. 891-892
Publisher Link: http://dx.doi.org/10.1183/09031936.00038713
Publisher: European Respiratory Society
Resource Type: journal article
Date: 2013
Description: Identifying and treating the eosinophilic subtype of asthma has now achieved renewed importance for clinicians and scientists involved in clinical trials. This has happened following the near-demise of an anti-interleukin (IL)-5 monoclonal antibody (mepolizumab) as a candidate for asthma treatment [1] and its resurrection in trials based around using induced sputum eosinophils to identify a treatment responsive phenotype [2, 3]. The improvement in outcome was spectacular. An effect size close to zero was converted to a massive effect size of a 50% reduction in asthma exacerbations, simply by using assessment of clinical status and eosinophils to identify a treatment responsive phenotype. The spotlight is now firmly on clinical trial design in airway diseases and how to identify disease subtypes for testing new therapies.
Subject: asthma; eosinophils; cytology; clinical trials; airway diseases
Identifier: http://hdl.handle.net/1959.13/1063509
Identifier: uon:17293
Identifier: ISSN:0903-1936
Language: eng

		Thumbnail	File	Description	Size	Format